Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 20/20 | 0.85 |
| ▸ | ADRB2 | P07550 | 19/20 | 0.85 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14166220 | 1.00 | CHRM3 (0.85) | CHRM3ADRB2CACNA1C | |
| SCHEMBL14695770 | 1.00 | CHRM3 (0.85) | CHRM3ADRB2CACNA1C | |
| SCHEMBL15772264 | 0.97 | CHRM3 (0.82) | CHRM3ADRB2CACNA1C | |
| SCHEMBL15772261 | 0.97 | CHRM3 (0.82) | CHRM3ADRB2CACNA1C | |
| SCHEMBL15772266 | 0.97 | CHRM3 (0.82) | CHRM3ADRB2CACNA1C | |
| SCHEMBL20357905 | 0.96 | CHRM3 (0.89) | CHRM3ADRB2CACNA1C | |
| SCHEMBL15772988 | 0.96 | CHRM3 (0.89) | CHRM3ADRB2CACNA1C | |
| SCHEMBL15772991 | 0.96 | CHRM3 (0.89) | CHRM3ADRB2CACNA1C | |
| SCHEMBL16213799 | 0.96 | CHRM3 (0.89) | CHRM3ADRB2CACNA1C | |
| SCHEMBL15772986 | 0.96 | CHRM3 (0.89) | CHRM3ADRB2CACNA1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2718280-B1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARMA SPA (IT) | 2015-09-16 | — | — | EP | claimed |
| US-8877774-B2 | Compounds having muscarinic receptor antagonist and beta2 Adrenergic receptor agonist activity | CHIESI FARMACEUTICI S.P.A. (IT) | 2014-11-04 | — | — | US | claimed |
| US-20130045169-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARMACEUTICI S.P.A. (IT) | 2013-02-21 | — | — | US | claimed |
| EP-2718280-B1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARMA SPA (IT) | 2015-09-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130045169-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | ADRB2, ADRB1, ADRA2B | CHRM3 11/4885ADRB2 1/4885CACNA1C 701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.